云南省甲型H1N1流感疫苗上市后的安全性观察  

Post-marketing Safety Observation of Influenza A (H1N1) Vaccine in Yunnan Province

作　　者：李凯[1] 罗梅[1] 黄国斐[1] 龚琼宇[1] 丁峥嵘[1] 万蓉[1] 彭敏[1] 

机构地区：[1]云南省疾病预防控制中心免疫规划科,云南昆明650022

出　　处：《昆明医科大学学报》2013年第5期82-85,共4页Journal of Kunming Medical University

基　　金：国家自然科学基金资助项目(81160198);云南省社会发展科技计划应用基础研究(2010CD118)

摘　　要：目的评价云南省使用的甲型H1N1流感(简称甲流)疫苗上市后的安全性.方法统计分析2012年3月29日至4月3日云南省2个乡镇自愿接种甲流疫苗人员在接种后28 d内不良反应发生情况及反应特征.结果在5 262名自愿接种疫苗人员中,共观察到接种不良反应52例,均为一般反应,全部痊愈.不良反应总发生率0.99%,其中局部反应发生率是0.32%,全身反应发生率是0.89%.常见不良反应主要是发热、疼痛、红肿和瘙痒.结论云南省使用的甲流疫苗具有较好的安全性,适宜无接种禁忌人群的普遍接种.Objective To assess the post-marketing safety of influenza A （H1N1） vaccine in Yunnan province. Methods Volunteers lived in two towns were inoculated by influenza A （HINI） vaccine from March 29 to April 3, 2012. The features of adverse reactions were observed and analyzed during 28 days after immunization. Results Among 5 262 volunteers inoculated, adverse reactions were found in 52 cases and all of them were common adverse reactions including fever, pain at the injection site, erythema swelling and itching. All cases were cured. The total incidence of adverse reaction was 0.99%, with the local reaction of 0.32% and systemic reaction of 0.89%. Conclusion Influenza A （H1N1） vaccine used in Yunnan has good safety, and it is suitable for a mass immunization in common population without contraindications.

关 键 词：甲型H1N1流感 疫苗 安全性 

分 类 号：R186[医药卫生—流行病学] R511.7[医药卫生—公共卫生与预防医学]